key: cord-0909357-45t1bm0m
authors: Zhao, Chaohui Lisa; Rapkiewicz, Amy; Maghsoodi-Deerwester, Mona; Gupta, Mala; Cao, Wenqing; Palaia, Thomas; Zhou, Jianhong; Ram, Bebu; Vo, Duc; Rafiee, Behnam; Hossein-Zadeh, Zarrin; Dabiri, Bahram; Hanna, Iman
title: Pathological findings in the postmortem liver of COVID-19 patients
date: 2020-12-08
journal: Hum Pathol
DOI: 10.1016/j.humpath.2020.11.015
sha: 76098126f745339d5a194d0cad7d4adf8d51ddce
doc_id: 909357
cord_uid: 45t1bm0m

INTRODUCTION: Although COVID-19 is transmitted via respiratory droplets, there are multiple gastrointestinal and hepatic manifestations of the disease, including abnormal liver-associated enzymes. However, there are not many published articles on the pathological findings in the liver of COVID-19 patients. METHODS: We collected the clinical data from 17 autopsy cases of COVID-19 patients including age, sex, BMI, liver function test (ALT, AST, ALP, direct bilirubin and total bilirubin), D-dimer and anticoagulation treatment. We examined histopathologic findings in postmortem hepatic tissue, immunohistochemical (IHC) staining with antibody against COVID spike protein, CD68 and CD61, and electron microscopy. We counted the number of megakaryocytes in liver sections from these COVID-19 positive cases. RESULTS: Abnormal liver-associated enzymes were observed in 12/17 cases of COVID-19 infection. With the exception of three cases that had not been tested for D-dimer, all 14 patients’ D-dimer levels were increased, including the cases that received varied doses of anticoagulation treatment. Microscopically, the major findings were widespread platelet-fibrin microthrombi, steatosis, histiocytic hyperplasia in the portal tract, mild lobular inflammation, ischemic-type hepatic necrosis and zone 3 hemorrhage. Rare megakaryocytes were found in sinusoids. COVID IHC demonstrates positive staining of the histiocytes in the portal tract. Under electron microscopy, histiocyte proliferation is present in the portal tract containing lipid droplets, lysosomes, dilated ribosomal endoplasmic reticulum (RER), micro-vesicular bodies and coronavirus. CONCLUSIONS: The characteristic findings in COVID-19 patients’ liver include numerous amounts of platelet-fibrin microthrombi as well as various degrees of steatosis and histiocytic hyperplasia in the portal tract. Possible mechanisms are also discussed.

We collected the clinical data from 17 autopsy cases of COVID-19 patients including 23 age, sex, BMI, liver function test (ALT, AST, ALP, direct bilirubin and total bilirubin), D-dimer 24 and anticoagulation treatment. We examined histopathologic findings in postmortem hepatic 25 tissue, immunohistochemical (IHC) staining with antibody against COVID spike protein, CD68 26 and CD61, and electron microscopy. We counted the number of megakaryocytes in liver sections 27 from these COVID-19 positive cases.

Results: Abnormal liver-associated enzymes were observed in 12/17 cases of infection. With the exception of three cases that had not been tested for D-dimer, all 14 patients' 31 D-dimer levels were increased, including the cases that received varied doses of anticoagulation 32 treatment. Microscopically, the major findings were widespread platelet-fibrin microthrombi, 33 steatosis, histiocytic hyperplasia in the portal tract, mild lobular inflammation, ischemic-type 34 hepatic necrosis and zone 3 hemorrhage. Rare megakaryocytes were found in sinusoids. COVID patients who were infected were observed in a substantial proportion (from 16% to 60%) of 58 patients, although generally only mildly elevated [2] [3] [4] [5] . Some papers showed that more severe The phenomenon of the liver involvement in 

The study was performed in accordance with the ethical guidelines and approval from the 

The clinical presentation of the 17 cases were summarized in Table 1 for the patient's age, sex, 140 BMI, past medical history, viral serologies, peak ALT, peak AST, peak ALP, total bilirubin, 141 direct bilirubin, liver weight, peak D-dimer, anticoagulation treatment and the level of the last D- 3.3 Liver function test: Abnormal liver-associated enzymes were observed in 12/17 cases. AST 158 was increased in 12 cases including 4 cases which were significantly increased (>3500 IU/L).

ALT was increased in 11 cases including 5 cases which were significantly increased (>1200 160 IU/L). ALP was increased in 6 cases. However, only mild increase of bilirubin was 161 appreciated (8 cases for direct bilirubin and 2 cases for total bilirubin). (Table 1 ) except for case 13 which had a large acute territorial infarction and as 167 such tissue plasminogen activator (TPA) was not given due to aortic dissection. Table 2 ). , 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 16) with 4 cases grade 2 and 8 cases grade 1 195 steatosis. The majority of cases (7 out of 12 cases) showed a predominant 196 macrovesicular pattern, while 4 cases were mixed macrovesicular/microvesicular 197 pattern, and only one case was predominantly microvesicular pattern. 3, 5, 6, 9, 13, 15, 16) . Ischemic-212 type hepatic necrosis was noted in 2 out of 17 cases (Case 3, 6). Figure 3C ), dilated rough endoplasmic reticulum (RER; Figure 3D ) and micro-vesicular 229 bodies ( Figure 3E) . A virion-like particle was seen in Figure 3F at approximately 80nm in In our autopsy cases, platelet-fibrin microthrombi were found in 12 out of the 17 cases (70%). Table 1 ), which was not related to the COVID-19 infection.

Even though we had 17 cases, the numbers of megakaryocytes were only counted in 13 cases 267 because of the variable levels of autolysis in the remaining four cases. Abnormal liver-associated enzymes were observed in the majority of our autopsy cases.

Moreover, some cases presented significantly increased liver-associated enzymes. In addition, 312 microscopically, lobular inflammation with scattered acidophil bodies were present. including antibiotics and experimental antiviral drugs that were utilized in these patients.

Steatosis is a common finding in these COVID-19 autopsies. There may be two reasons for 339 steatosis. One is that the patients have a high BMI. Another is that it may be due to hypoxia and 

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus 356 pneumonia in Wuhan, China: a descriptive study

Gastrointestinal and Liver Manifestations of COVID-19

Gastrointestinal and liver manifestations of COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVID-19 and Liver

Single cell RNA sequencing of 13 human tissues identify cell types and receptors of 365 human coronaviruses

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the 367 potential risk of different human organs vulnerable to 2019-nCoV infection

Megakaryocytes and platelet-fibrin thrombi characterize multi-organ 370 thrombosis at autopsy in COVID-19: A case series. EClinicalMedicine

Quantifying hepatic steatosis -more than meets the eye

Ultrastructural characterization of SARS coronavirus

Pathological findings of COVID-19 associated with acute respiratory distress 377 syndrome

Pathological study of the 2019 novel coronavirus disease (COVID-19) through 379 postmortem core biopsies

Hepatic pathology in patients dying of COVID-19: a series of 40 cases 381 including clinical, histologic, and virologic data

Platelets in inflammation and infection

Neutrophil extracellular traps in immunity and disease

Histiocytic hyperplasia with hemophagocytosis and acute alveolar 387 damage in COVID-19 infection

The biological function and significance of CD74 in immune diseases

Identification of the invariant chain (CD74) as an angiotensin AGTR1-391 interacting protein

Immune responses in COVID-19 and potential 393 vaccines: Lessons learned from SARS and MERS epidemic

Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei

China: A Descriptive, Cross-Sectional, Multicenter Study

Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in 401 Covid-19

Epstein-Barr Virus Hepatitis: A Review of Clinicopathologic Features 403 and Differential Diagnosis

COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic 405 Strategies

An ALOX12-12-HETE-GPR31 signaling axis is a key mediator of hepatic 407 ischemia-reperfusion injury

Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-409 2alpha/PPARalpha pathway

Number of the case (%) Features of COVID infection Platelet-fibrin thrombi in sinusoid